Literature DB >> 9620738

Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators.

J G Cleland, K Swedberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620738     DOI: 10.1016/s0140-6736(05)77712-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  31 in total

Review 1.  Heart failure in 10 years time: focus on pharmacological treatment.

Authors:  J J V McMurray
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

Review 2.  Natriuretic peptides in cardiovascular diseases: current use and perspectives.

Authors:  Massimo Volpe; Speranza Rubattu; John Burnett
Journal:  Eur Heart J       Date:  2013-11-13       Impact factor: 29.983

Review 3.  Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.

Authors:  Paul M McKie; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 4.  Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.

Authors:  Stuart B Prenner; Sanjiv J Shah; Clyde W Yancy
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

Review 5.  Neprilysin Inhibitors in Cardiovascular Disease.

Authors:  Guson Kang; Dipanjan Banerjee
Journal:  Curr Cardiol Rep       Date:  2017-02       Impact factor: 2.931

6.  The Role of Neprilysin Inhibitors in Cardiovascular Disease.

Authors:  Jared Mills; Orly Vardeny
Journal:  Curr Heart Fail Rep       Date:  2015-12

7.  Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?

Authors:  Sam Hayman; John J Atherton
Journal:  Card Fail Rev       Date:  2016-05

Review 8.  Drug therapy in chronic heart failure.

Authors:  D B McKenzie; A J Cowley
Journal:  Postgrad Med J       Date:  2003-11       Impact factor: 2.401

Review 9.  Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Authors:  Scott A Hubers; Nancy J Brown
Journal:  Circulation       Date:  2016-03-15       Impact factor: 29.690

Review 10.  Modulation of cGMP in heart failure: a new therapeutic paradigm.

Authors:  Guido Boerrigter; Harald Lapp; John C Burnett
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.